A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

被引：1
|
作者：
Liu, Wei [1 ]
Huang, Yunhong [2 ]
Yang, Haiyan [3 ]
Li, Zhiming [4 ]
Cai, Zhen [5 ]
Wang, Zhen [6 ]
Liu, Lihong [7 ]
Guo, Ye [8 ]
Liu, Ligen [9 ]
Huang, Rui [10 ]
Ye, Xu [11 ]
Qiu, Lugui [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp,Haihe Lab Cell Ecos, Tianjin, Peoples R China
[2] Guizhou Med Univ, Affiliated Canc Hosp, Guiyang, Peoples R China
[3] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[4] State Key Lab Oncol South China, Guangzhou, Peoples R China
[5] Zhejiang Univ, Sch Med, Bone Marrow Transplantat Ctr, Affiliated Hosp 1, Hangzhou, Peoples R China
[6] Linyi Canc Hosp, Linyi, Peoples R China
[7] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
[8] Shanghai East Hosp, Shanghai, Peoples R China
[9] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Shanghai, Peoples R China
[10] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China
[11] Guangzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Guangzhou, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-177550
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Genomic Characterization of Patients in a Phase 2 Study of Zanubrutinib in BTK Inhibitor-Intolerant Patients with Relapsed/Refractory B-Cell Malignancies
    Xu, Linlin
    Shadman, Mazyar
    Ponakala, Anusha
    Flinn, Ian W.
    Levy, Moshe Yair
    Porter, Ryan
    Burke, John M.
    Zafar, Syed F.
    Cultrera, Jennifer L.
    Misleh, Jamal
    Kingsley, Edwin C.
    Yimer, Habte
    Freeman, Benjamin
    Chaudhry, Arvind
    Tumula, Praveen K.
    Gandhi, Mitul
    Cohen, Aileen
    Chen, Dih-Yih
    Manda, Sudhir
    Sharman, Jeff P.
    Ramakrishnan, Vanitha
    BLOOD, 2022, 140 : 9269 - 9271
  • [22] Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma
    Munakata, Wataru
    Shirasugi, Yukari
    Tobinai, Kensei
    Onizuka, Makoto
    Makita, Shinichi
    Suzuki, Rikio
    Maruyama, Dai
    Kawai, Hidetsugu
    Izutsu, Koji
    Nakanishi, Tadashi
    Shiba, Sari
    Hojo, Seichiro
    Ando, Kiyoshi
    CANCER SCIENCE, 2021, 112 (03) : 1123 - 1131
  • [23] Selinexor in Combination with R-GDP for Patients with Relapsed/Refractory B-Cell Lymphoma: Results of the Selinda Phase Ib Lysa Study
    Maerevoet, Marie
    Casasnovas, Olivier
    Cartron, Guillaume
    Morschhauser, Franck
    Thieblemont, Catherine
    Bouabdallah, Kamal
    Feugier, Pierre
    Szablewski, Vanessa
    Becker, Stephanie
    Tilly, Herve
    BLOOD, 2021, 138
  • [24] Entospletinib and obinutuzumab in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell malignancies
    Kittai, Adam S.
    Best, Scott
    Thurlow, Bria
    Lam, Vi
    Hashiguchi, Taylor
    Goodyear, Shaun
    Persky, Daniel O.
    Okada, Craig
    Park, Byung
    Spurgeon, Stephen E.
    Danilov, Alexey V.
    HAEMATOLOGICA, 2021, 106 (07) : 2022 - 2025
  • [25] A Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
    Qiu, Lugui
    Jin, Jie
    Cen, Hong
    Zhou, Keshu
    Xu, Xiaohong
    Li, Fei
    Wu, Tao
    Yang, Haiyan
    Wang, Zhen
    Li, Zhiming
    Bao, Hanying
    Xu, Zusheng
    BLOOD, 2022, 140 : 9395 - 9396
  • [26] Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies
    Roeker, Lindsey E.
    Coombs, Catherine C.
    Shah, Nirav N.
    Jurczak, Wojciech
    Woyach, Jennifer A.
    Cheah, Chan Y.
    Patel, Krish
    Maddocks, Kami
    Wang, Yucai
    Zinzani, Pier Luigi
    Munir, Talha
    Koh, Youngil
    Thompson, Meghan C.
    Muehlenbein, Catherine E.
    Wang, Chunxiao
    Sizelove, Richard
    Abhyankar, Sarang
    Hasanabba, Safarulla
    Tsai, Donald E.
    Eyre, Toby A.
    Wang, Michael
    ACTA HAEMATOLOGICA, 2024,
  • [27] Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
    Bartlett, Nancy L.
    Assouline, Sarit
    Giri, Pratyush
    Schuster, Stephen J.
    Cheah, Chan Y.
    Matasar, Matthew
    Gregory, Gareth P.
    Yoon, Dok Hyun
    Shadman, Mazyar
    Fay, Keith
    Yoon, Sung-Soo
    Panizo, Carlos
    Flinn, Ian
    Johnston, Anna
    Bosch, Francesc
    Sehn, Laurie H.
    Wei, Michael C.
    Yin, Shen
    To, Iris
    Li, Chi-Chung
    Huang, Huang
    Kwan, Antonia
    Penuel, Elicia
    Budde, Lihua E.
    BLOOD ADVANCES, 2023, 7 (17) : 4926 - 4935
  • [28] BENDAMUSTINE MONOTHERAPY IN ELDERLY PATIENTS AFFECTED BY RELAPSED OR REFRACTORY B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
    Lucania, A.
    Esposito, M.
    Della Cioppa, P.
    Improta, S.
    Mastrullo, L.
    HAEMATOLOGICA, 2015, 100 : 74 - 74
  • [29] Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan
    Munakata, Wataru
    Ando, Kiyoshi
    Hatake, Kiyohiko
    Fukuhara, Noriko
    Kinoshita, Tomohiro
    Fukuhara, Suguru
    Shirasugi, Yukari
    Yokoyama, Masahiro
    Ichikawa, Satoshi
    Ohmachi, Ken
    Gion, Naokazu
    Aoi, Arata
    Tobinai, Kensei
    CANCER SCIENCE, 2019, 110 (05) : 1686 - 1694
  • [30] Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study
    Hamlin, Paul A.
    Flinn, Ian W.
    Wagner-Johnston, Nina
    Burger, Jan A.
    Coffey, Greg P.
    Conley, Pamela B.
    Michelson, Glenn
    Leeds, Janet M.
    Der, Kenneth
    Kim, Yvonne
    Sabalvaro-Torres, Alice
    Birrell, Matt
    Pandey, Anjali
    Curnutte, John T.
    Patel, Manish R.
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (04) : E90 - E93
12345